Studies on the predictive factors of treatment outcome after intravitreal injection of Lucentis (ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (CRVO)
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2018
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Central retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- 27 May 2018 Status changed from recruiting to completed.
- 15 May 2014 New source identified and integrated (ClinicalTrials.gov record: NCT02091505).
- 17 Mar 2014 According to the ClinicalTrials.gov record, planned end date changed to 1 May 2016.